I

I-MAB
D

IMAB

1.08000
USD
-0.01
(-0.92%)
Market Open
Volume
5,431
EPS
0
Div Yield
0
P/E
-0
Market Cap
83,782,873
OverviewSignalsIdeasNews
Related Instruments
    I
    IHRT
    -0.06000
    (-3.37%)
    1.72000 USD
    I
    IMAX
    0.078
    (0.37%)
    21.188 USD
    I
    IMPL
    0
    (0%)
    0.000000 USD
    I
    IMRN
    0.15000
    (6.12%)
    2.60000 USD
    I
    IMTE
    0.09000
    (5.42%)
    1.75000 USD
    I
    IMV
    0.01000
    (1.96%)
    0.51000 USD
    More
News

Title: I/MAB

Sector: Healthcare
Industry: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).